Navigation Links
Positive results for airway bypass
Date:10/9/2007

Mountain View, CA, October 9, 2007 - Broncus Technologies, Inc., a medical device company investigating the airway bypass procedure for the treatment of emphysema, today announced that the results of its open-label Exhale Drug-Eluting Stent feasibility study have been published in the October issue of the Journal of Thoracic and Cardiovascular Surgery. Positive results include a statistically significant reduction in the amount of air trapped in the lungs and an improvement in breathing for patients at six months after the airway bypass procedure.

Airway bypass is a catheter-based bronchoscopic procedure designed to reduce lung hyperinflation and improve breathlessness (the clinical hallmarks of emphysema/COPD) by making new pathways for trapped air to exit the lungs. During the minimally invasive procedure, new openings are created in the airway wall connecting the damaged lung tissue to the natural airway. These pathways are supported and kept open by Exhale Drug-Eluting Stents. The hope is to improve quality of life by relieving severe symptoms including shortness of breath and hyperinflation of the chest.

Emphysema, a component of COPD, is a chronic, progressive, and irreversible lung disease characterized by the destruction of lung tissue. The loss of the lungs' natural elasticity and the collapse of airways in the lung combine to make exhalation ineffective, leaving emphysema sufferers with hyperinflation because they are unable to get air out of their lungs. Breathing becomes inefficient and patients have to work very hard just to breathe making normal activities, like walking, eating or even bathing, difficult. Treatment options for most patients with emphysema are currently limited and generally result in anguished patients and frustrated physicians.

The prospectively-defined primary endpoint of this feasibility study was a reduction in residual volume (RV, the amount of air remaining in the lungs after full exhalation) at 6 months. The goal was for a 300mL reduction in RV. Overall the trial surpassed that goal with a 400mL improvement in RV over baseline at 6 months (p=0.04). Patients also showed a statistically significant improvement in the modified Medical Research Council Dyspnea Scale (mMRC), a breathlessness test, of -0.5 points (p= 0.025). Retrospective analysis revealed that patients with the most severe hyperinflation of their lungs (as determined by a residual volume to total lung capacity ratio above the median) derived the greatest benefit from airway bypass. At 6 months after the procedure, these patients showed a mean improvement in RV of 870mL (p=0.022).

The management of emphysema poses a difficult challenge for the medical community as the disease progressively deprives patients of their ability to perform daily activities. These findings are encouraging because there are so few options for the millions patients who suffer from this disease, states Paulo F.G. Cardoso, M.D., Ph.D, Division of Thoracic Surgery, Santa Casa de Porto Alegre-Pavilhao Pereira Filho Hospital, Brazil and lead author of the paper. These results reveal significant improvements in pulmonary function and reduction in breathing difficulties out to six months and indicate that airway bypass is a potentially viable therapeutic option for patients with marked severe pulmonary destruction, whose only current option may be to wait for a lung transplant.

The data from this study are very exciting, as they help build the case that airway bypass might reduce hyperinflation and have long-term benefit, states Cary Cole, CEO of Broncus. We hope to continue this success with the current, pivotal EASE Trial, our largest clinical study to date.


'/>"/>

Contact: Meghan Oreste
moreste@comcast.net
617-823-1441
Broncus Technologies
Source:Eurekalert

Related biology news :

1. Neurologix announces positive results of gene therapy clinical trial in Parkinsons disease
2. Insight into the processes of positive and negative learners
3. HIV-infected adults in Botswana respond positively to ARV therapy public treatment program
4. Malaria treatment efficacy compromised in certain HIV-positive patients
5. To slow AIDS in Russia, treat HIV-positive addicts, Stanford study says
6. Gene vaccine for Alzheimers disease shows promising results
7. Roche clinical trial registry and results database launched
8. Diabetic nerve therapy shows striking results
9. Results of worlds first gene therapy trial for arthritis show approach safe, feasible
10. New results validating Pall prion reduction filter disclosed at ISBT Congress
11. Tramiprosate (Alzhemed? preclinical results published in Neurobiology of Aging
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/22/2016)...  The American College of Medical Genetics and Genomics was ... as one of the fastest-growing trade shows during the Fastest ... in Las Vegas . ... in each of the following categories: net square feet of ... attendees. The 2015 ACMG Annual Meeting was ranked 23 out ...
(Date:6/20/2016)... DALLAS , June 20, 2016 ... criminal justice technology solutions for public safety, investigation, ... by the prisons involved, it has secured the ... Corrections (DOC) facilities for Managed Access Systems (MAS) ... (4) additional facilities to be installed by October, ...
(Date:6/9/2016)... June 9, 2016 Paris ... Teleste,s video security solution to ensure the safety of people ... during the major tournament Teleste, an international ... and services, announced today that its video security solution will ... to back up public safety across the country. The system ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... BOSTON , June 27, 2016   Ginkgo ... biology to industrial engineering, was today awarded as ... a selection of the world,s most innovative companies. ... at scale for the real world in the ... organism engineers work directly with customers including Fortune ...
(Date:6/24/2016)... ... June 24, 2016 , ... Researchers at the Universita Politecnica delle Marche in ... peritoneal or pleural mesothelioma. Their findings are the subject of a new article on ... biomarkers are signposts in the blood, lung fluid or tissue of mesothelioma patients that ...
(Date:6/23/2016)... June 23, 2016 /PRNewswire/ - FACIT has announced ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" ... commercialization of a portfolio of first-in-class WDR5 inhibitors ... such as WDR5 represent an exciting class of ... precision medicine for cancer patients. Substantial advances have ...
(Date:6/23/2016)... SANTA MONICA, Calif. , June 23, 2016  The Prostate Cancer ... to pioneer increasingly precise treatments and faster cures for prostate cancer. Members of ... 77 institutions across 15 countries. Read More About the ... ... ...
Breaking Biology Technology: